NT-proBNP does not improve evaluation of syncope in the ED

NT-proBNP does not improve evaluation of syncope in the ED

(HealthDay)—For adult emergency department (ED) patients with syncope, serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) does not improve prognostication above the Canadian Syncope Risk Score (CSRS), according to a study published online April 28 in the Annals of Internal Medicine.

Venkatesh Thiruganasambandamoorthy, M.B.B.S., from the University of Ottawa in Ontario, Canada, and colleagues conducted a involving 1,452 adult ED with syncope to examine whether adding NT-proBNP to the CSRS improves prediction of 30-day serious adverse events (SAEs).

The researchers found that 10.5 percent of the participants had 30-day SAEs; 3.9 percent were identified after the index ED disposition. Compared with those without SAEs, patients with SAEs had significantly higher serum NT-proBNP concentrations (median, 626.5 versus 81 ng/L). There was no significant improvement in prognostication with the addition of NT-proBNP values to the CSRS (C-statistic, 0.89 and 0.90, respectively), regardless of SAE subgroup or whether the SAE was identified after the index ED visit. NT-proBNP would have correctly reclassified 3 percent of patients with SAEs at the expense of incorrectly reclassifying 2 percent of those without SAEs based on the net reclassification index.

"Our results indicate that NT-proBNP measurement is unlikely to be useful in the routine ED work-up of syncope," the authors write.

One author disclosed financial ties to Medtronic.


Explore further

Canadian syncope risk score IDs ED monitoring time postsyncope

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: NT-proBNP does not improve evaluation of syncope in the ED (2020, April 30) retrieved 21 January 2021 from https://medicalxpress.com/news/2020-04-nt-probnp-syncope-ed.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments